

CHIBBER

Appl. No. 10/584,470


November 23, 2009

**AMENDMENTS TO THE CLAIMS:**


This listing of claims will replace all prior versions, and listings, of claims in the application:

1-76 (cancelled)


77 (currently amended). A method of treatment of a condition associated with raised activity of the enzyme Core 2 GlcNAc-T comprising administration of an effective amount of a compound of the formula I formula IV to a patient in need thereof



wherein R<sub>4</sub> is OH, C<sub>1-6</sub> alkoxy, NR<sub>8</sub>R<sub>9</sub>, or a monosaccharide of the formula IIa;



R<sub>2</sub> is OH, C<sub>1-6</sub> alkoxy or a monosaccharide of the formula IIb;




CHIBBER

Appl. No. 10/584,470

November 23, 2009

~~R<sub>3</sub> is OH, C<sub>1-6</sub> alkoxy or a monosaccharide of the formula IIc;~~



~~R<sub>4</sub> is C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-hydroxyalkyl or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl;~~


~~R<sub>5</sub> is C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-hydroxyalkyl or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl;~~

~~R<sub>6</sub> is C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-hydroxyalkyl or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl;~~

~~R<sub>7</sub> is C<sub>2-6</sub>-alkyl, C<sub>1-6</sub>-hydroxyalkyl or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl;~~

~~R<sub>8</sub> is H, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-acyl;~~

~~R<sub>9</sub> is H, C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-acyl, and~~




IV

CHIBBER

Appl. No. 10/584,470

November 23, 2009

Z is a steroid group, and Z is either a group of the formula VII:



VII

wherein:

R<sub>12</sub>, R<sub>13</sub>, R<sub>15</sub> and R<sub>28</sub> each represent H;

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>16</sub> is H, or =O;


R<sub>17</sub> is H or -OH;

R<sub>18</sub> is H or -OH;

R<sub>19</sub> is H, or -CH<sub>3</sub>;

R<sub>20</sub> is -OH or C<sub>1-6</sub> alkoxy;

R<sub>21</sub> is of the formula VIII;



VIII

CHIBBER

Appl. No. 10/584,470

November 23, 2009

R<sub>22</sub> is H, -OH, or -OMe;

R<sub>23</sub> is -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>OH, -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>24</sub> is C<sub>1-6</sub> alkyl, C<sub>1-6</sub> acyl, or glucose;


R<sub>29</sub> is H or -OH;

R<sub>32</sub> is H or -OH;

R<sub>33</sub> is H; and

Y is O;

or a group of the formula XI:



wherein:

R<sub>12</sub>, R<sub>13</sub>, R<sub>15</sub> and R<sub>28</sub> each represent H;

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>16</sub> is H, or =O;

R<sub>17</sub>, R<sub>18</sub>, R<sub>25</sub>, R<sub>29</sub>, R<sub>31</sub>, R<sub>32</sub>, and R<sub>34</sub> are independently selected from H and -OH;

R<sub>19</sub> is H, or -CH<sub>3</sub>;

CHIBBER

Appl. No. 10/584,470

November 23, 2009

R<sub>26</sub> is -CH<sub>2</sub>H<sub>4</sub>OH, -CH<sub>2</sub>OH, -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>33</sub> is H; and

X is O or NH;

or a pharmaceutically acceptable salt, ester or tautomeric form or derivative

thereof; and

wherein said condition associated with raised activity of the enzyme Core 2 GlcNAc-T is selected from the group consisting of an inflammatory disease, asthma, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, diabetic cardiomyopathy, myocardial dysfunction, cancer, cancer metastasis or and diabetic retinopathy, and

~~wherein the cancer to be treated is selected from the group consisting of leukaemia, oral cavity carcinomas, pulmonary cancers such as pulmonary adenocarcinoma, colorectal cancer, bladder carcinoma, liver tumours, stomach tumours colon tumours, prostate cancer, testicular tumour, mammary cancer, lung tumours oral cavity carcinomas and any cancers where Core 2 GlcNAc-T expression is raised above normal levels for that tissue type.~~





78-120 (cancelled).

121 (currently amended). A method of according to Claim 102 77 in which the steroid group of the formula (VII) is selected from a the group consisting of:

CHIBBER

Appl. No. 10/584,470

November 23, 2009



wherein:

R<sub>18</sub> is H or -OH;

R<sub>20</sub> is -OH or C<sub>1-6</sub> alkoxy;

R<sub>24</sub> is glucose or C<sub>1-6</sub> acyl; and

R<sub>29</sub> is H or -OH.

122 (currently amended). A method of according to Claim 77 in which the compound of the formula I formula IV is selected from the group consisting of:  
trigoneoside IVa which is (3 $\beta$ ,25S)-26-( $\beta$ -D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]- $\beta$ -D-glucopyranoside, glycoside F which is (3 $\beta$ )-26-( $\beta$ -D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]- $\beta$ -D-glucopyranoside, shatavarin I, compound 3,

CHIBBER


Appl. No. 10/584,470

November 23, 2009


pardarinoside C.

123-142 (cancelled).


143 (currently amended). A method of according to Claim 134\_77 in which the steroid group of the formula XI is selected from the group consisting of:




A




B




C



D



E



F

144 (currently amended). A method of according to Claim 134 77 in which the steroid group of the formula XI is selected from the group consisting of diosgenin, yamogenin, tigogenin, neotigogenin, sarsasapogenin, smilagenin, hecogenin, solasodine or tomatidine.

145 (currently amended). A method of Claim 77 in which the compounds compound of the formula-I formula IV are selected from the group consisting of:

Shatavarin IV which is sarsasapogenin 3-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]- $\beta$ -D-glucopyranoside,


Compound 12 which is solasodine 3-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]- $\beta$ -D-glucopyranoside,

Deltonin which is (3 $\beta$ ,25R)-spirost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]- $\beta$ -D-Glucopyranoside, and

Balanitin VI is (3 $\beta$ ,25S)-spirost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]- $\beta$ -D-Glucopyranoside.

146-151 (cancelled).

152 (previously presented). A compound of the formula:



153 (cancelled).

154 (new). A method according to Claim 77 wherein, in the group of the formula (VII);

$R_{12}$ ,  $R_{13}$ ,  $R_{15}$ ,  $R_{16}$ ,  $R_{17}$ ,  $R_{22}$ ,  $R_{28}$  and  $R_{32}$  each represent H;

$R_{14}$  is H, or  $R_{14}$  and  $R_{33}$  taken together represent the second bond of a double bond joining adjacent carbon atoms;

$R_{18}$  is H or -OH;

$R_{19}$  is  $-CH_3$ ;

$R_{20}$  is -OH or  $C_{1-6}$  alkoxy;

$R_{21}$  is of the formula VIII;

CHIBBER  
Appl. No. 10/584,470  
November 23, 2009

R<sub>23</sub> is -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>24</sub> is C<sub>1-6</sub> acyl or glucose;

R<sub>29</sub> is H or -OH;

R<sub>33</sub> is H; and

Y is O.

155 (new). A method according to Claim 77 wherein, in the formula (XI);

R<sub>12</sub>, R<sub>13</sub>, R<sub>15</sub>, R<sub>16</sub>, R<sub>17</sub>, R<sub>25</sub>, R<sub>28</sub>, R<sub>31</sub>, R<sub>32</sub> and R<sub>34</sub>, each represent H;

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>18</sub> is H or -OH;

R<sub>19</sub> is -CH<sub>3</sub>;

R<sub>26</sub> is -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>29</sub> is H or -OH;

R<sub>33</sub> is H; and


X is O or NH.

156 (new). A method according to Claim 77 wherein, in the compound of the formula (IV) is selected from:

CHIBBER

Appl. No. 10/584,470

November 23, 2009




157 (new). A method of treatment of a condition selected from an inflammatory disease, asthma, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, diabetic cardiomyopathy, myocardial dysfunction, cancer metastasis and diabetic retinopathy, comprising administering to a patient in need thereof, an extract of fenugreek, said extract being essentially free of hypoglycemic activity and comprising an effective amount of a compound of the formula (IV)


CHIBBER

Appl. No. 10/584,470

November 23, 2009



wherein Z is a group of the formula VII:



wherein:

R<sub>12</sub>, R<sub>13</sub>, R<sub>15</sub> and R<sub>28</sub> each represent H;

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>16</sub> is H, or =O;

CHIBBER

Appl. No. 10/584,470

November 23, 2009


R<sub>17</sub> is H or -OH;

R<sub>18</sub> is H or -OH;

R<sub>19</sub> is H, or -CH<sub>3</sub>;

R<sub>20</sub> is -OH or C<sub>1-6</sub> alkoxy;

R<sub>21</sub> is of the formula VIII;



R<sub>22</sub> is H, -OH, or -OMe;

R<sub>23</sub> is -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>OH, -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>24</sub> is C<sub>1-6</sub> alkyl, C<sub>1-6</sub> acyl, or glucose;


R<sub>29</sub> is H or -OH;

R<sub>32</sub> is H or -OH;

R<sub>33</sub> is H; and

Y is O;

or Z is a group of the formula XI:



wherein:

R<sub>12</sub>, R<sub>13</sub>, R<sub>15</sub> and R<sub>28</sub> each represent H;

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>16</sub> is H, or =O;

R<sub>17</sub>, R<sub>18</sub>, R<sub>25</sub>, R<sub>29</sub>, R<sub>31</sub>, R<sub>32</sub>, and R<sub>34</sub> are independently selected from H and -OH;

R<sub>19</sub> is H, or -CH<sub>3</sub>;

R<sub>26</sub> is -CH<sub>2</sub>OH, -CH<sub>2</sub>OH, -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>33</sub> is H; and

X is O or NH;

or a pharmaceutically acceptable salt, ester or tautomeric form thereof.

158 (new). A method according to Claim 157 wherein, in the group of the formula (VII);

R<sub>12</sub>, R<sub>13</sub>, R<sub>15</sub>, R<sub>16</sub>, R<sub>17</sub>, R<sub>22</sub>, R<sub>28</sub> and R<sub>32</sub> each represent H;

CHIBBER

Appl. No. 10/584,470

November 23, 2009

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>18</sub> is H or -OH;

R<sub>19</sub> is -CH<sub>3</sub>;

R<sub>20</sub> is -OH or C<sub>1-6</sub> alkoxy;

R<sub>21</sub> is of the formula VIII;

R<sub>23</sub> is -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>24</sub> is C<sub>1-6</sub> acyl or glucose;

R<sub>29</sub> is H or -OH;

R<sub>33</sub> is H; and


Y is O.

159 (new). A method according to Claim 157 in which the group of the formula (VII) is selected from the group consisting of:

CHIBBER

Appl. No. 10/584,470

November 23, 2009



wherein:

R<sub>18</sub> is H or -OH;

R<sub>20</sub> is -OH or C<sub>1-6</sub> alkoxy;

R<sub>24</sub> is glucose or C<sub>1-6</sub> acyl; and

R<sub>29</sub> is H or -OH.

160 (new). A method according to Claim 157 in which the compound of the formula IV is selected from the group consisting of:

Trigoneoside IVa which is (3 $\beta$ ,25S)-26-( $\beta$ -D-glucopyranosyloxy)-22-hydroxy furost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]- $\beta$ -D-glucopyranoside, Glycoside F which is (3 $\beta$ )-26-( $\beta$ -D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-


CHIBBER

Appl. No. 10/584,470

November 23, 2009

$\beta$ -D-glucopyranoside, Shatavarin I, Compound 3, Pardarinoside C.

161 (new). A method according to Claim 156 in which the compound of the formula IV is selected from the group consisting of:



162 (new). A method according to Claim 157 wherein, in the formula (XI);

$R_{12}$ ,  $R_{13}$ ,  $R_{15}$ ,  $R_{16}$ ,  $R_{17}$ ,  $R_{25}$ ,  $R_{28}$ ,  $R_{31}$ ,  $R_{32}$  and  $R_{34}$ , each represent H;

CHIBBER  
Appl. No. 10/584,470  
November 23, 2009

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>18</sub> is H or -OH;

R<sub>19</sub> is -CH<sub>3</sub>;


R<sub>26</sub> is -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>29</sub> is H or -OH;

R<sub>33</sub> is H; and

X is O or NH.

163 (new). A method according to Claim 157 in which the group of the formula XI is selected from the group consisting of:



164 (new). A method according to Claim 157 in which the group of the formula XI is selected from the group consisting of diosgenin, yamogenin, tigogenin, neotigogenin, sarsasapogenin, smilagenin, hecogenin, solasodine or tomatidine.

165 (new). A method according to Claim 157 in which the compound of the formula IV is selected from the group consisting of:

Shatavarin IV which is sarsasapogenin 3-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-

CHIBBER

Appl. No. 10/584,470

November 23, 2009

glucopyranosyl-(1→4)]- $\beta$ -D-glucopyranoside,


Compound 12 which is solasodine 3-O- $\alpha$ -L-rhamnopyranosyl-(1→2)-O-[ $\beta$ -D-glucopyranosyl-(1→4)]- $\beta$ -D-glucopyranoside,

Deltonin which is (3 $\beta$ ,25R)-spirost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1→2)-O-[ $\beta$ -D-glucopyranosyl-(1→4)]- $\beta$ -D-Gluco- pyranoside, and

Balanitin VI is (3 $\beta$ ,25S)-spirost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1→2)-O-[ $\beta$ -D-glucopyranosyl-(1→4)]- $\beta$ -D-Glucopyranoside.

166 (new). A method according to Claim 157 wherein said plant extract is a component of a pharmaceutical composition which additionally comprises a pharmaceutically acceptable diluent or excipient.

167 (new). An isolated compound of the formula:




168 (new). A method of treatment of a condition selected from an inflammatory disease, asthma, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, diabetic cardiomyopathy, myocardial dysfunction, cancer metastasis and diabetic retinopathy, comprising administering to a patient in need thereof, an extract of fenugreek, said extract being essentially free of 4-hydroxyisoleucine and comprising an effective amount of a compound of the formula (IV)


CHIBBER

Appl. No. 10/584,470

November 23, 2009



wherein Z is a group of the formula VII:



wherein:

R<sub>12</sub>, R<sub>13</sub>, R<sub>15</sub> and R<sub>28</sub> each represent H;

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>16</sub> is H, or =O;


R<sub>17</sub> is H or -OH;

R<sub>18</sub> is H or -OH;

R<sub>19</sub> is H, or -CH<sub>3</sub>;

R<sub>20</sub> is -OH or C<sub>1-6</sub> alkoxy;

R<sub>21</sub> is of the formula VIII;



R<sub>22</sub> is H, -OH, or -OMe;

R<sub>23</sub> is -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>OH, -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>24</sub> is C<sub>1-6</sub> alkyl, C<sub>1-6</sub> acyl, or glucose;


R<sub>29</sub> is H or -OH;

R<sub>32</sub> is H or -OH;

R<sub>33</sub> is H; and

Y is O;

or Z is a group of the formula XI:



wherein:

R<sub>12</sub>, R<sub>13</sub>, R<sub>15</sub> and R<sub>28</sub> each represent H;

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>16</sub> is H, or =O;

R<sub>17</sub>, R<sub>18</sub>, R<sub>25</sub>, R<sub>29</sub>, R<sub>31</sub>, R<sub>32</sub>, and R<sub>34</sub> are independently selected from H and -OH;

R<sub>19</sub> is H, or -CH<sub>3</sub>;

R<sub>26</sub> is -CH<sub>2</sub>H<sub>4</sub>OH, -CH<sub>2</sub>OH, -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>33</sub> is H; and

X is O or NH;

or a pharmaceutically acceptable salt, ester or tautomeric form thereof.

169 (new). A method according to Claim 168 wherein, in the group of the formula (VII);

R<sub>12</sub>, R<sub>13</sub>, R<sub>15</sub>, R<sub>16</sub>, R<sub>17</sub>, R<sub>22</sub>, R<sub>28</sub> and R<sub>32</sub> each represent H;

CHIBBER

Appl. No. 10/584,470

November 23, 2009

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>18</sub> is H or -OH;

R<sub>19</sub> is -CH<sub>3</sub>;

R<sub>20</sub> is -OH or C<sub>1-6</sub> alkoxy;

R<sub>21</sub> is of the formula VIII;

R<sub>23</sub> is -CH<sub>3</sub> or =CH<sub>2</sub>;


R<sub>24</sub> is C<sub>1-6</sub> acyl or glucose;

R<sub>29</sub> is H or -OH;

R<sub>33</sub> is H; and

Y is O.

170 (new). A method according to Claim 168 in which the group of the formula (VII) is selected from the group consisting of:



wherein:

R<sub>18</sub> is H or -OH;

R<sub>20</sub> is -OH or C<sub>1-6</sub> alkoxy;

R<sub>24</sub> is glucose or C<sub>1-6</sub> acyl; and

R<sub>29</sub> is H or -OH.

171 (new). A method according to Claim 168 in which the compound of the formula IV is selected from the group consisting of:

Trigoneoside IVa which is (3 $\beta$ ,25S)-26-( $\beta$ -D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]- $\beta$ -D-glucopyranoside,


Glycoside F which is (3 $\beta$ )-26-( $\beta$ -D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]- $\beta$ -D-glucopyranoside,

CHIBBER

Appl. No. 10/584,470  
November 23, 2009

Shatavarin I, Compound 3, Pardarinoside C.

172 (new) A method according to Claim 168 in which the compound of the formula IV is selected from the group consisting of:



173 (new). A method according to Claim 168 wherein, in the formula (XI);  
 $R_{12}, R_{13}, R_{15}, R_{16}, R_{17}, R_{25}, R_{28}, R_{31}, R_{32}$  and  $R_{34}$ , each represent H;

CHIBBER

Appl. No. 10/584,470

November 23, 2009

R<sub>14</sub> is H, or R<sub>14</sub> and R<sub>33</sub> taken together represent the second bond of a double bond joining adjacent carbon atoms;

R<sub>18</sub> is H or -OH;

R<sub>19</sub> is -CH<sub>3</sub>;

R<sub>26</sub> is -CH<sub>3</sub> or =CH<sub>2</sub>;

R<sub>29</sub> is H or -OH;

R<sub>33</sub> is H; and


X is O or NH.

174 (new). A method according to Claim 168 in which the group of the formula XI is selected from the group consisting of:

CHIBBER

Appl. No. 10/584,470

November 23, 2009



175 (new). A method according to Claim 168 in which the group of the formula XI is selected from the group consisting of diosgenin, yamogenin, tigogenin, neotigogenin, sarsasapogenin, smilagenin, hecogenin, solasodine or tomatidine.

176 (new). A method according to Claim 168 in which the compound of the formula IV is selected from the group consisting of:

Shatavarin IV which is sarsasapogenin 3-O- $\alpha$ -L-rhamnopyranosyl-(1 $\rightarrow$ 2)-O-[ $\beta$ -D-

CHIBBER

Appl. No. 10/584,470

November 23, 2009

glucopyranosyl-(1→4)]- $\beta$ -D-glucopyranoside,

Compound 12 which is solasodine 3-O- $\alpha$ -L-rhamnopyranosyl-(1→2)-O-[ $\beta$ -D-glucopyranosyl-(1→4)]- $\beta$ -D-glucopyranoside,

Deltonin which is (3 $\beta$ ,25R)-spirost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1→2)-O-[ $\beta$ -D-glucopyranosyl-(1→4)]- $\beta$ -D-Gluco- pyranoside, and

Balanitin VI is (3 $\beta$ ,25S)-spirost-5-en-3-yl-O- $\alpha$ -L-rhamnopyranosyl-(1→2)-O-[ $\beta$ -D-glucopyranosyl-(1→4)]- $\beta$ -D-Glucopyranoside.

177 (new). A method according to Claim 168 wherein said plant extract is a component of a pharmaceutical composition which additionally comprises a pharmaceutically acceptable diluent or excipient.

178 (new). A method according to either Claim 157 or Claim 168 wherein said plant extract is a fenugreek extract.

179 (new). A method according to either Claim 157 or Claim 168 wherein said plant extract is an extract of fenugreek seeds.